

Aision Biotechnologies

Rebecca Brachman, Ph.D.
Co-founder
www.aisionbio.com
rebecca@aisionbio.com



Industry: Pharma

Management:

Executive Leadership

Rebecca Brachman
(Cofounder)

Scientific Advisory Board

Christine Ann Denny, Ph.D.
(Cofounder)
René Hen, Ph.D.
Donald Landry, M.D., Ph.D.

Number of Employees: 1

Finance:

Amount of Financing Sought:
\$1.8 million

Legal:

Pending patent application,
with 1 additional filing
anticipated in the next year

Executive Summary:

Aision Bio is a pre-clinical stage pharmaceutical company focused on developing primary prophylaxis for psychiatric disorders. We have discovered the first compounds ever that may protect against psychiatric diseases, such as depression and post-traumatic stress disorder (PTSD). This represents a paradigm shift in psychiatry; using pharmacotherapy to *prevent* mental illness—rather than just treat it—is an entirely novel approach.

Company History:

Aision is built upon fundamental research originating from Columbia University.

Market Opportunity / Unmet Need:

Surpassing HIV/AIDS, malaria, diabetes, and war, depression is now the leading cause of disability worldwide. Affecting 350 million people, the burden of mental illness continues to rise globally. It is estimated that the global cost is nearly \$2.5-3 trillion, greater than the entirety of overseas development aid over the past twenty years. We are creating a new market and a new class of drugs. There are no existing primary prophylactic treatments against mental illness.

Products/Services – Launched & Pipeline:

Our pipeline consists of several compounds at the hit-to-lead stage of development, as well as less developed pre-clinical assets in distinct molecular classes.

Commercial / Technical Milestones:

We plan to initiate IND-enabling studies in 1 year with our identified lead molecule, moving to Phase I by year 2 and entering Phase II by year 3. Anticipated commercial milestones include early-stage strategic partnerships with the DoD, out-licensing following completion of Phase II studies, or continuance to Phase III, with approval by year 10.

Intellectual Property:

We have submitted 1 non-provisional patent application, and anticipate a second patent filing within the next year.

Competition:

Behavioral resilience training programs.

Financial Projections (Unaudited):

Search and discovery funds: \$300,000
Required funds through IND-enabling studies: \$1.5 million

Please indicate primary purpose of Presentation: Business development, partnership, philanthropic and bridge funding.